The global antinuclear antibody test market revenue was around US$ 1.3 billion in 2021 and is estimated to reach US$ 4.5 billion by 2030, growing at a compound annual growth rate (CAGR) of 15% during ...

GSK plc (LSE/NYSE: GSK) today announced the launch of the Linked by Lupus: Optimal Care Initiative to help support ...

CD19-CAR T-cell treatment is a novel option of deep B cell depletion with promising results across different rheumatologic ...

Discover how autoimmune conditions target joints, causing pain and inflammation. Learn about 7 conditions, symptoms, and ...

Called enpatoran, the agent targets the Toll-like receptor (TLR) species 7 and 8. Some 50%-60% of patients with systemic ...

CD19-CAR T-cell treatment is a novel option of deep B cell depletion with promising results across different rheumatologic and musculoskeletal diseases (RMD). This and other cell-depleting approaches ...

When receiving a diagnosis of a rheumatic musculoskeletal disease (RMD), people need a lot of information. Some need it all ...

Germany’s Merck KGaA has presented detailed results from cohort B of the global Phase II WILLOW study of enpatoran, an ...

Objective One key target of treating patients with systemic lupus erythematosus (SLE) is to prevent organ damage. This analysis quantified the association between time spent in four specific SLE low ...